Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review

[1]  T. Helleday,et al.  Zebularine induces replication-dependent double-strand breaks which are preferentially repaired by homologous recombination. , 2017, DNA repair.

[2]  A. Loriot,et al.  Oncogenic roles of DNA hypomethylation through the activation of cancer-germline genes. , 2017, Cancer letters.

[3]  A. Becker,et al.  DNA methylation signature for the assessment of metastatic risk in primary renal cell cancer. , 2017 .

[4]  Jeffrey A. Engelman,et al.  Prospects for combining targeted and conventional cancer therapy with immunotherapy , 2017, Nature Reviews Cancer.

[5]  B. Christensen,et al.  Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine , 2016, Oncotarget.

[6]  M. Spinella,et al.  Epigenetic Targeting of Platinum Resistant Testicular Cancer. , 2016, Current cancer drug targets.

[7]  W. Ji,et al.  Long non-coding RNA DBCCR1-003 regulate the expression of DBCCR1 via DNMT1 in bladder cancer , 2016, Cancer Cell International.

[8]  Shahrokh F. Shariat,et al.  An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer , 2016, Biomolecules.

[9]  T. Ho,et al.  DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas , 2016, Clinical Cancer Research.

[10]  M. Lorincz,et al.  Long Terminal Repeats: From Parasitic Elements to Building Blocks of the Transcriptional Regulatory Repertoire. , 2016, Molecular cell.

[11]  P. Munster,et al.  Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. , 2016, Immunotherapy.

[12]  J. Stoye,et al.  Immune responses to endogenous retroelements: taking the bad with the good , 2016, Nature Reviews Immunology.

[13]  Xiao-hou Wu,et al.  5-azacytidine inhibits the proliferation of bladder cancer cells via reversal of the aberrant hypermethylation of the hepaCAM gene. , 2016, Oncology reports.

[14]  M. Beckmann,et al.  Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses , 2016, Cell.

[15]  Aaron J. Johnson,et al.  Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1. , 2016, The Journal of clinical investigation.

[16]  J. Herman,et al.  Epigenome-based personalized medicine in human cancer. , 2016, Epigenomics.

[17]  Xin Hu,et al.  Epigenetic synergy between decitabine and platinum derivatives , 2015, Clinical Epigenetics.

[18]  Trevor J Pugh,et al.  DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts , 2015, Cell.

[19]  A. Verma,et al.  Role of DNA methylation in renal cell carcinoma , 2015, Journal of Hematology & Oncology.

[20]  Michael S. Goldberg,et al.  Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model , 2015, Cancer Immunology Research.

[21]  Jana Jeschke,et al.  DNA methylome profiling beyond promoters – taking an epigenetic snapshot of the breast tumor microenvironment , 2015, The FEBS journal.

[22]  Z. Herceg,et al.  Genome-wide methylation and transcriptome analysis in penile carcinoma: uncovering new molecular markers , 2015, Clinical Epigenetics.

[23]  R. Singal,et al.  Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy. , 2015, Clinical genitourinary cancer.

[24]  S. Beck,et al.  Epigenetics Markers of Metastasis and HPV-Induced Tumorigenesis in Penile Cancer , 2014, Clinical Cancer Research.

[25]  D. Matei,et al.  The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer , 2014, Clinical Cancer Research.

[26]  J. Martinez-Picado,et al.  Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA‐methyltransferase inhibitors , 2014, British journal of pharmacology.

[27]  L. Hesson,et al.  The evidence for functional non-CpG methylation in mammalian cells , 2014, Epigenetics.

[28]  F. Abbas,et al.  Promoter hypermethylation of tumor suppressor genes correlates with tumor grade and invasiveness in patients with urothelial bladder cancer , 2014, SpringerPlus.

[29]  K. Miller,et al.  Functional Epigenetic Analysis of Prostate Carcinoma: A Role for Seryl-tRNA Synthetase? , 2014, Journal of biomarkers.

[30]  K. Miller,et al.  An Epigenetic Screen Unmasks Metallothioneins as Putative Contributors to Renal Cell Carcinogenesis , 2014, Urologia Internationalis.

[31]  Peter A. Jones,et al.  Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers , 2014, Oncotarget.

[32]  B. Yin,et al.  Aberrant DNA methyltransferase 1 expression in clear cell renal cell carcinoma development and progression. , 2014, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[33]  T. Heidmann,et al.  Endogenous retroviruses: acquisition, amplification and taming of genome invaders. , 2013, Current opinion in virology.

[34]  G. Peters,et al.  Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360) , 2013, Investigational New Drugs.

[35]  C. Ricketts,et al.  Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma , 2013, Clinical Epigenetics.

[36]  J. Workman,et al.  Nucleosome remodeling and epigenetics. , 2013, Cold Spring Harbor perspectives in biology.

[37]  A. Besaratinia,et al.  Alterations of DNA methylome in human bladder cancer , 2013, Epigenetics.

[38]  M. Sabatino,et al.  Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin , 2013, Epigenetics.

[39]  F. Marchi,et al.  Epigenetic Mechanisms in Penile Carcinoma , 2013, International journal of molecular sciences.

[40]  Solomon H. Snyder,et al.  Erratum: Inositol polyphosphate multikinase is a coactivator of p53-mediated transcription and cell death (Science Signaling (2013) 6: 273 (er1) Doi: 10.1126/scisignal.6273er1) , 2013 .

[41]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[42]  M. Maio,et al.  Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide , 2013, Cancer Immunology, Immunotherapy.

[43]  D. Weisenberger,et al.  3-D DNA methylation phenotypes correlate with cytotoxicity levels in prostate and liver cancer cell models , 2013, BMC Pharmacology and Toxicology.

[44]  B. Christensen,et al.  Acute Hypersensitivity of Pluripotent Testicular Cancer-Derived Embryonal Carcinoma to Low-Dose 5-Aza Deoxycytidine Is Associated with Global DNA Damage-Associated p53 Activation, Anti-Pluripotency and DNA Demethylation , 2012, PloS one.

[45]  Peter Bouwman,et al.  The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance , 2012, Nature Reviews Cancer.

[46]  Jin-hee Kim,et al.  Fluorocyclopentenyl-cytosine with broad spectrum and potent antitumor activity. , 2012, Journal of medicinal chemistry.

[47]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[48]  D. Matei,et al.  Epigenetic resensitization to platinum in ovarian cancer. , 2012, Cancer research.

[49]  Nita Ahuja,et al.  Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. , 2012, Cancer cell.

[50]  E. Ostrander,et al.  Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development. , 2011, The Journal of urology.

[51]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[52]  Thomas Lengauer,et al.  Genomic Distribution and Inter-Sample Variation of Non-CpG Methylation across Human Cell Types , 2011, PLoS genetics.

[53]  G. Sonpavde,et al.  Epigenetics in Prostate Cancer , 2011, Prostate cancer.

[54]  Peter A. Jones,et al.  DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. , 2011, Human molecular genetics.

[55]  G. Sonpavde,et al.  Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer. , 2011, Urologic oncology.

[56]  K. Chiam,et al.  GSTP1 DNA Methylation and Expression Status Is Indicative of 5-aza-2′-Deoxycytidine Efficacy in Human Prostate Cancer Cells , 2011, PloS one.

[57]  B. Christensen,et al.  Polycomb group genes are targets of aberrant DNA methylation in renal cell carcinoma , 2011, Epigenetics.

[58]  N Clarke,et al.  Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma , 2011, Oncogene.

[59]  I. Ng,et al.  Transcriptional Repressive H3K9 and H3K27 Methylations Contribute to DNMT1-Mediated DNA Methylation Recovery , 2011, PloS one.

[60]  S. Thorgeirsson,et al.  An Integrated Genomic and Epigenomic Approach Predicts Therapeutic Response to Zebularine in Human Liver Cancer , 2010, Science Translational Medicine.

[61]  J. Richter,et al.  Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance , 2010, The Journal of pathology.

[62]  M. T. McCabe,et al.  Long-term Stability of Demethylation after Transient Exposure to 5-Aza-2′-Deoxycytidine Correlates with Sustained RNA Polymerase II Occupancy , 2010, Molecular Cancer Research.

[63]  Y. Bang,et al.  DNA methyltransferase 3-like affects promoter methylation of thymine DNA glycosylase independently of DNMT1 and DNMT3B in cancer cells. , 2010, International journal of oncology.

[64]  Peter A. Jones,et al.  S110, a 5-Aza-2′-Deoxycytidine–Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor In vivo and Can Reduce Tumor Growth , 2010, Molecular Cancer Therapeutics.

[65]  E. Dmitrovsky,et al.  High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors. , 2009, Cancer research.

[66]  Lee E. Edsall,et al.  Human DNA methylomes at base resolution show widespread epigenomic differences , 2009, Nature.

[67]  J. Herman,et al.  A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors , 2009, Clinical Cancer Research.

[68]  Vincenza Dolo,et al.  Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. , 2009, Endocrine-related cancer.

[69]  Laura Vidal,et al.  Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.

[70]  Razelle Kurzrock,et al.  Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers , 2008, Clinical Cancer Research.

[71]  J. Hicks,et al.  Global DNA hypomethylation in intratubular germ cell neoplasia and seminoma, but not in nonseminomatous male germ cell tumors , 2008, Modern Pathology.

[72]  Ioannis Panagopoulos,et al.  Promoter analysis of epigenetically controlled genes in bladder cancer , 2008, Genes, chromosomes & cancer.

[73]  H. Moon,et al.  Synthesis and Antitumor Activity of Fluorocyclopentenyl-Pyrimidines , 2007, Nucleosides, nucleotides & nucleic acids.

[74]  R. Lothe,et al.  The epigenome of testicular germ cell tumors , 2007, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[75]  Gangning Liang,et al.  Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. , 2007, Cancer research.

[76]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[77]  C. Pérez-Plasencia,et al.  A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors , 2007, BMC Cancer.

[78]  J. Köllermann,et al.  Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer , 2006, British Journal of Cancer.

[79]  E. Borden,et al.  Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  F. Monzon,et al.  Methylation of the ASC gene promoter is associated with aggressive prostate cancer , 2006, The Prostate.

[81]  Stephanie Daignault,et al.  Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. , 2006, Cancer research.

[82]  Peter A. Jones,et al.  Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine , 2005, Molecular Cancer Therapeutics.

[83]  W. J. Choi,et al.  Design, synthesis, and anticancer activity of fluorocyclopentenyl-pyrimidines. , 2005, Nucleic acids symposium series.

[84]  Frank Lyko,et al.  Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. , 2005, Cancer research.

[85]  V. Marquez,et al.  Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells. , 2005, Biochemical Pharmacology.

[86]  K. Camphausen,et al.  Enhancement of In vitro and In vivo Tumor Cell Radiosensitivity by the DNA Methylation Inhibitor Zebularine , 2005, Clinical Cancer Research.

[87]  M. Carducci,et al.  Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  P. M. Das,et al.  DNA methylation and cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  W. Linehan,et al.  The In vitro and In vivo Effects of Re-Expressing Methylated von Hippel-Lindau Tumor Suppressor Gene in Clear Cell Renal Carcinoma with 5-Aza-2′-deoxycytidine , 2004, Clinical Cancer Research.

[90]  J. Bacik,et al.  Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors , 2004, Molecular Cancer.

[91]  Peter A. Jones,et al.  Continuous Zebularine Treatment Effectively Sustains Demethylation in Human Bladder Cancer Cells , 2004, Molecular and Cellular Biology.

[92]  Peter A. Jones,et al.  Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. , 2004, Molecular cancer research : MCR.

[93]  David A Jones,et al.  Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. , 2004, Molecular pharmacology.

[94]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[95]  Ni Ai,et al.  Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. , 2003, Cancer research.

[96]  Manel Esteller,et al.  Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. , 2003, Cancer research.

[97]  Wei Ye,et al.  Inhibition of DNA methylation and reactivation of silenced genes by zebularine. , 2003, Journal of the National Cancer Institute.

[98]  O. Ogawa,et al.  Multipoint methylation and expression analysis of tumor suppressor genes in human renal cancer cells. , 2003, Urology.

[99]  V. Reuter,et al.  Characteristic promoter hypermethylation signatures in male germ cell tumors , 2002, Molecular Cancer.

[100]  Peter A. Jones,et al.  Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. , 2002, Cancer research.

[101]  Daiya Takai,et al.  Comprehensive analysis of CpG islands in human chromosomes 21 and 22 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[102]  J. Minna,et al.  Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. , 2001, Cancer research.

[103]  S. Eddy.  Non–coding RNA genes and the modern RNA world , 2001, Nature Reviews Genetics.

[104]  T. Ohnishi,et al.  Activation of the MN/CA9 gene is associated with hypomethylation in human renal cell carcinoma cell lines , 2000, Molecular carcinogenesis.

[105]  H. Albertsen,et al.  Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[106]  A. Macleod,et al.  Down-regulation of Human DNA-(Cytosine-5) Methyltransferase Induces Cell Cycle Regulators p16 ink4A and p21WAF/Cip1 by Distinct Mechanisms* , 1999, The Journal of Biological Chemistry.

[107]  Patricia A. Elder,et al.  Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. , 1998, Genomics.

[108]  M. Grunstein.  Histone acetylation in chromatin structure and transcription , 1997, Nature.

[109]  R. Jaenisch,et al.  Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[110]  J. Abbruzzese,et al.  Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells. , 1990, Cancer research.